While no change in the overall frequency of CD8+ T cells was observed at this early time point, tumor infiltrating CD8+ T cells tended to display a more activated phenotype (i.e., CD69+), which was also reflected in the splenic T cell population (Fig. S28 Motivated by these data, we studied the tumor and spleen immune cell dynamics after treatment with one, two, or three doses of AP-diABZI (Fig. 6, Fig. S29–30). This evidence concerns the gene CD69 and neoplasm.